Nasdaqcompany
DevelopingMarket movement

Citi Downgrades Moderna to Sell, Saying a $200 Share Price Needs $26 Billion in Cancer Sales

Citi cut Moderna to Sell from Neutral and lifted its target to $80, saying a $200 share price would need about $26 billion in annual cancer sales; MRNA fell 8.57% premarket.

Why it matters

Citi cut the rating and raised the price target in the same note, a pairing that leaves Moderna's cancer pipeline rather than its near-term share price doing the work in the valuation debate. For tokenized equities, MRNAB keeps quoting while the underlying Nasdaq stock is closed, so its 24-hour change will not line up with an ordinary premarket decline.

Key facts

Moderna shares fell 8.57% to $186.03 in Wednesday premarket trading following the Citi downgrade.

8.57 %Reported by The Crypto Basic

Citi moved Moderna from Neutral to Sell.

Reported by The Crypto Basic

Citi raised its Moderna price target to $80 from $60 while cutting the rating.

80 USDReported by The Crypto Basic

Citi's net-present-value analysis supports about $100 per share even with a 100% probability assigned to intismeran's leading cancer programs.

100 USDReported by The Crypto Basic

Citi analyst Geoff Meacham said Moderna's valuation assumes substantially more oncology success than Citi forecasts and that investors still need to see a strong treatment effect.

Reported by The Crypto Basic

Moderna Tokenized bStock (MRNAB) traded at $187.79, down 3.91% over the previous 24 hours according to CoinMarketCap, a period that differs from the Nasdaq premarket move because MRNAB trades around the clock.

3.91 %Reported by The Crypto Basic

What happened

The Crypto Basic reports that Moderna shares on Nasdaq (MRNA) fell 8.57% to $186.03 in Wednesday premarket trading after Citi downgraded the stock from Neutral to Sell. The same note raised Citi's price target to $80 from $60, and analyst Geoff Meacham said the market value assumes substantially more oncology success than Citi forecasts. Citi estimates that holding a share price near $200 would require roughly $26 billion in annual cancer sales, about $13 billion of it accruing to Moderna, which the bank puts at nearly seven times its own oncology forecast, while its net-present-value work supports about $100 per share even at full probability of success for intismeran's leading cancer programs. The decline came after a 3.13% Tuesday gain that closed Moderna at $203.46 on a new 52-week high of $208.90. Tokenized stock Moderna Tokenized bStock (MRNAB) was quoted at $187.79, down 3.91% over the previous 24 hours according to CoinMarketCap, a window that does not match the premarket session because MRNAB trades around the clock. No second outlet in this desk's evidence covers the downgrade, and The Crypto Basic's account cuts off mid-sentence during Meacham's remarks, so the remainder of his argument is not on record here.

How the story developed

  1. First report

    First report by The Crypto Basic

    Moderna Stock Falls Over 8% Premarket as Citi Says $200 Price Would Require $26 Billion in Cancer Sales

    The Crypto Basic

  2. Update

    Citi downgrades Moderna to Sell and MRNA falls in premarket trading

    The Crypto Basic reports the downgrade, the target increase to $80 from $60, the $26 billion annual cancer-sales requirement behind a $200 share price, and the MRNAB quote from CoinMarketCap.

    The Crypto Basic

Affected entities

Original sources

PublisherReportRolePublished
The Crypto Basic
Crypto media
Moderna Stock Falls Over 8% Premarket as Citi Says $200 Price Would Require $26 Billion in Cancer SalesOriginal